Synbio International Inc. announced that it has signed a Master Services Agreement with CRO Services Pty Ltd, a subsidiary of Resonance Health Ltd. Under the agreement, CRO Services will conduct a proof-of-concept clinical trial in Australia to evaluate the efficacy of FacialDx Incorporated’s NIMS™ (Non-invasive Medical Screening) technology. The trial will assess the performance of the AI-powered facial analysis screening software for mental health disorders, such as Post-Traumatic Stress Disorder and Major Depressive Disorder, in real-world clinical conditions. The data from the study is intended to support future regulatory submissions and inform Synbio’s commercialization strategy in healthcare and corporate markets. The trial is expected to begin in early 2026, pending finalization of related agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Synbio International Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 1AXXF7E6y) on January 15, 2026, and is solely responsible for the information contained therein.